Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature
| Autor: | Omar M Ismail, Mohamad A Yassin, Nancy Kassem, Halima El-Omri |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Oncology medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Side effect Stomach Diseases Adenomatous Polyps 03 medical and health sciences Polyps 0302 clinical medicine Recurrence Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine Tyrosine Kinase Inhibitors (TKI) medicine Humans neoplasms Chronic Myelogenous Leukemia business.industry Myeloid leukemia Imatinib Articles General Medicine Middle Aged Protein-Tyrosine Kinases Nilotinib medicine.disease digestive system diseases respiratory tract diseases Leukemia Pyrimidines Gastric Polyp 030220 oncology & carcinogenesis BCR-ABL Positive business Tyrosine kinase 030215 immunology Chronic myelogenous leukemia medicine.drug |
| Zdroj: | The American Journal of Case Reports |
| ISSN: | 1941-5923 |
| Popis: | Patient: Male, 62 Final Diagnosis: Chronic myeloid leukemia Symptoms: Gastric polyps Medication: Nilotinib Clinical Procedure: — Specialty: Hematology Objective: Unusual or unexpected effect of treatment Background: Tyrosine kinase inhibitors (TKIs) are currently an important targeted drug class in the treatment of chronic myeloid leukemia (CML). Imatinib was the first approved TKI for CML in 2001. Nilotinib is a second-generation TKI, approved in 2007; it inhibits BCR-ABL, PDGFR, and c-KIT, and is 30 times more potent than imatinib. Tyrosine kinase enzymes are expressed in multiple tissues and are involved in several signaling pathways; they have been shown to have several off-target side effects. Case Report: We report a case of an elderly male with CML and no history of gastrointestinal diseases, treated with nilotinib, and developed recurrent gastric polyps after three years of treatment. We excluded common causes of gastric polyps and therefore considered nilotinib as a probable cause of recurrent gastric polyps. Conclusions: Recurrent gastric polyps could be a potential side effect of nilotinib treatment. Careful long-term monitoring of patients on TKI therapy is necessary and further long-term studies of TKI side effects are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|